Navigation Links
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Date:12/21/2007

HORSHAM, Pa. and KENILWORTH, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced they have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE(R) (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which is currently in Phase 3 trials. Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough's rights to exclusively market REMICADE in its current marketing territories outside the United States beyond 2014 to match the current duration of its exclusive marketing rights for golimumab product. Schering-Plough's marketing rights to both products will now extend for 15 years after the first golimumab commercial sale.

In addition, Centocor will receive a progressively increased share of profits on Schering-Plough's distribution of both products in the Schering-Plough marketing territory between 2010 and 2014, and remaining fixed thereafter for the remainder of the term.

The revised agreement will also allow Schering-Plough to independently develop and market golimumab for the Crohn's disease indication in its territories, with an option for Centocor to participate in the program.

The parties have also agreed to utilize an autoinjector device developed by Centocor affiliate Cilag GmbH International in the commercialization of golimumab in their respective territories and have further agreed to share the autoinjector development costs. The autoinjector would allow patients to self-administer golimumab subcu
'/>"/>

SOURCE Schering-Plough Corporation; Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
10. NUCRYST and Smith & Nephew Revise Agreements
11. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ because ... said Steve Young of Ew Publishing; “I’ve had cluster ... is more intense.” , “It should be a relief ... that medical research is pointing to some relief and ... Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found in ...
(Date:9/21/2014)... According to latest National Vital Statistics Reports ... (10.5 births per 1,000 women in 2013). Since 2000, the ... by 2 percent per year. The birth rate for women ... over) also rose, the first such increase since 2008. Ultimately ... as many first births to women aged 35 and older ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... 2014 Increases in household, construction ... waste treatment volumes. However, government regulations and higher ... landfill. According to IBISWorld industry analyst Alen Allday, ... aimed at reducing the volume of waste generated, ... recovered.” Still, a large proportion of waste generated ...
(Date:9/20/2014)... The print component of “Work-Life ... the Calgary Herald, with a circulation of approximately ... The digital component is distributed nationally through a ... of top news sites and partner outlets. To ... http://www.worklifebalanceinfo.ca . , The publication features an ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... , , , , ... action suit involving drug wholesaler McKesson Corporation and data publishers First Data Bank ... terms, according to Greg Ruc i nski , ... a leading next-generation health information business. , , "There,s ...
... NASHVILLE, Tenn., Aug. 11 Emdeon Inc. (the "Company") today ... of its Class A common stock at a price of $15.50 ... the Company and 12,975,000 were offered by selling stockholders. The shares ... ticker symbol "EM." To the extent that the underwriters sell more ...
... Study reiterates that young are most vulnerable , TUESDAY, Aug. ... is doing its part to make sure that doctors and ... link between antidepressant use and suicide, which indicate that the ... trials involving nearly 100,000 people who took antidepressants showed that ...
... , WEST PALM BEACH, Fla., Aug. 11 ... he a ring aids and hearing care announced ... designed exclusively for AARP members. The program is scheduled to be made available ... be extended to AARP members in all 50 states and the U.S. territories. ...
... , Dr. Mubin Syed evaluates findings; calls ... Aug. 11 A new study by Mayo Clinic researchers has ... vertebroplasty to treat osteoporotic spinal fractures. , , ... injected into vertebrae to relieve pain and improve mobility in patients ...
... , , Survey seeks ... , , CHICAGO, Aug. 11 Participate in ... to/publicsurvey and become eligible to win a $150 Amazon.com ... ADA.org. , , ADA.org provides news and information on hundreds ...
Cached Medicine News:Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 2Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 3Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 4Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 5Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Suicide Risk With Antidepressants Falls With Age 2Health News:Suicide Risk With Antidepressants Falls With Age 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 4Health News:Noted Vertebroplasty Expert Cites Concerns About Recently Published Study 2Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Delivers Unprecedented Specificity for ... Diagnosing ... Medical Solutions,Diagnostics (http://www.siemens.com/diagnostics ) announced that it has ... rights to develop an,automated stimulating TSH receptor antibody (TRAb) ...
... more effective than,tamoxifen at preventing breast cancer recurrence ... with hormone-responsive cancers. In addition, the increased,risk of ... being treated with,anastrozole disappears after treatment ends., ... Antonio Breast Cancer,Symposium, Professor John Forbes of the ...
Cached Medicine Technology:Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu 2Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu 3Anastrozole Confirmed Superior in Breast Cancer Prevention 2
... The advanced performance benefits of TiMAX™ ... generation of implants. DePuy ACEs Large Fragment ... biocompatibility and enhanced imaging compatibility over traditional ... unique thread design in the TiMAX bone ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... Fragment System has been conceived and engineered ... and user-friendly instrumentation. The modular system of ... instrumentation is designed to provide the surgeon ... and classic techniques of open reduction and ...
Medicine Products: